MedPath

Withings' Sleep Rx Mat Receives FDA 510(k) Clearance for OSA Diagnosis Assistance

• The FDA has granted 510(k) clearance to Withings' Sleep Rx Mat, a device designed to aid in the diagnosis of sleep apnea in adults. • The under-mattress mat tracks sleep, breathing, and cardiovascular activity, providing users with a sleep quality score and detailed sleep data. • The device uses pneumatic, sound, and motion sensors to monitor respiratory rate, heart rate, sleep cycles, snoring, and breathing disturbances. • Withings' VP, Antoine Robillard, highlights the potential for Sleep Rx to improve OSA diagnosis and reduce the economic burden of undiagnosed sleep apnea.

The Sleep Rx Mat, developed by Withings, has received 510(k) clearance from the FDA for its ability to assist in the diagnosis of obstructive sleep apnea (OSA) in adults. The device, which fits under any mattress, provides individuals with comprehensive data on their sleep patterns, breathing, and cardiovascular activity throughout the night.

Device Functionality and Features

The Sleep Rx Mat utilizes a combination of pneumatic, sound, and motion sensors to monitor various physiological parameters. These include respiratory rate, body movement, continuous heart rate, sleep cycles, and sleep duration. The device also identifies instances of snoring and breathing disturbances, providing a detailed overview of the user's sleep health. After a night of use, individuals receive an easy-to-understand sleep quality score, facilitating a better understanding of their sleep patterns.

Clinical Significance and Impact

Antoine Robillard, Vice President of Withings Health Solutions, emphasized the importance of early and accurate OSA diagnosis. "Enabling earlier and more precise diagnosis, Sleep Rx creates a new sleep apnea diagnosis and management paradigm," said Robillard. He also noted that traditional one-night assessments are often insufficient for accurate diagnosis. Data from a previous study involving over 11.6 million nights of monitoring with the Withings Sleep Analyzer revealed that a significant proportion of adults had varying degrees of OSA, with misdiagnosis rates ranging from 20% to 50% in single-night studies. Extended monitoring periods reduced these error rates, stabilizing after 14 nights.

Potential Economic Benefits

Undiagnosed sleep apnea carries a substantial economic burden, estimated at $150 billion annually. By enabling more efficient and lower-cost home-based OSA diagnosis, Sleep Rx has the potential to significantly reduce this burden and improve long-term health outcomes, according to Withings.

Prescription Requirement

The Sleep Rx Mat requires a prescription for purchase, ensuring that its use is guided by medical professionals.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Reference News

[1]
FDA grants 510(k) clearance to under-mattress device that assists in OSA diagnosis - Healio
healio.com · Sep 11, 2024

The FDA granted 510(k) clearance to the Sleep Rx Mat, an under-mattress device aiding in OSA diagnosis by tracking respi...

© Copyright 2025. All Rights Reserved by MedPath